DOJ Moves FDA-Approved and State-Licensed Medical Marijuana Products to Schedule III
On April 23, 2026, the Department of Justice and Drug Enforcement Administration issued an order placing FDA-approved marijuana products, along with medicinal marijuana products covered by a qualifying state-issued license, into Schedule III of the Controlled Substances Act. The action implements President Trump's December 18, 2025, Executive Order on Increasing Medical Marijuana and Cannabidiol Research. The DOJ also announced an expedited administrative hearing, beginning June 29, 2026, to consider broader rescheduling of marijuana from Schedule I to Schedule III. Officials framed the action as expanding research access and patient care while preserving federal controls.
Read the full press release here.